Camouflage and sabotage: tumor escape from the immune system

Cancer Immunology, Immunotherapy · Published 2011-08-01 · Available online 6 Apr 2011 · Journal article · DOI 10.1007/s00262-011-1012-8 · Cited by 148 (Crossref)

Authors (3)

Isabel Poschke, Dimitrios Mougiakakos, Rolf Kiessling

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

60

Issue

8

Pages

1161-1171

Year

2011

Citation

Poschke, I., Mougiakakos, D., Kiessling, R. (2011). Camouflage and sabotage: tumor escape from the immune system. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-011-1012-8

Related articles

• Thyroid Cancer: From Potential Drivers to Real Modulators · Cancers · 2026 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

148